Lapatinib (Tykerb) did not add benefit to the standard trastuzumab (Herceptin) adjuvant therapy in the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, researchers report at the 50th annual meeting of the American Society of Clinical Oncology (ASCO)/a. MULTIMEDIA ALERT: Video and audio are available for download on the Mayo Clinic News Network/a. Results of the phase III clinical ...
Read More
No comments:
Post a Comment